Mark Kirschbaum

Research Field

Supplementary Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

Leo Kretzner Anna Scuto Pamela M. Dino Claudia Kowolik Jun Wu

Supplementary Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

Vorinostat

Histone deacetylase inhibitor

10.1158/0008-5472.22395189.v1

Cite

Citations (0)

Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Joseph M. Tuscano Emanual Maverakis Susan Groshen Denice Tsao‐Wei Guillaume Luxardi

<p>Supplementary Figure 6</p>

Refractory (planetary science)

10.1158/1078-0432.22472463.v1

Cite

Citations (0)

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Blood (2005)

Richard Piekarz Robin Frye Maria L. Turner James R. Wright Steven L. Allen

Depsipeptide

Cutaneous T-cell lymphoma

Romidepsin

10.1182/blood.v106.11.231.231

Cite

Citations (25)

A Radiation-Free Immune and Epigenetics Based Conditioning Regimen for Allogeneic HCT: Combination of Anti-CD3 and Romidepsin.

Blood (2006)

Nainong Li Chunyan Zhang Chia-Lei Lin Bill McCulloch James R. Wright

Romidepsin

Minimal Residual Disease

10.1182/blood.v108.11.3204.3204

Cite

Citations (3)

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Blood (2009)

Olatoyosi Odenike Emily Curran Neil M. Iyengar Leslie Popplewell Mark Kirschbaum

10.1182/blood.v114.22.2081.2081

Cite

Citations (7)

Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors

Advances in cancer research (1999)

Leah N. Klapper Mark Kirschbaum Michael Seta Yosef Yarden

Neuregulin

ErbB

10.1016/s0065-230x(08)60784-8

Cite

Citations (548)

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Blood (2013)

Robert Chen Paul Frankel Leslie Popplewell Tanya Siddiqi Wei Ye

Vorinostat

Refractory (planetary science)

Follicular lymphoma

Tolerability

10.1182/blood.v122.21.4398.4398

Cite

Citations (2)

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

Blood (1998)

Shimon Slavin Arnon Nagler E Naparstek Y. Kapelushnik Memet Aker

Total body irradiation

Donor lymphocyte infusion

10.1182/blood.v91.3.756

Cite

Citations (1,774)

hENT1 and Hodgkin lymphoma: Not just crossing the channel

Leukemia & lymphoma/Leukemia and lymphoma (2008)

Mark Kirschbaum

Discussion of treatment options in advanced Hodgkin lymphoma (HL) tends to be somewhat dialectical-higher rates of responses can be obtained with intensification of therapy, but these may be accomp...

Classical Hodgkin lymphoma

10.1080/10428190802163297

Cite

Citations (1)

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

British Journal of Haematology (2015)

Susan E. Bates Robin A. Eisch Alexander Ling Douglas R. Rosing Maria L. Turner

Summary Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T‐cell lymphoma ( CTCL and PTCL ). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long‐term disease control and the ability to retreat patients relapsing off‐therapy. In all, 84 patients with CTCL and 47 with PTCL were enrolled. Responses occurred early, were clinically meaningful and of very long duration in some cases. Notably, patients with PTCL receiving romidepsin as third‐line therapy or later had a comparable response rate (32%) of similar duration as the total population (38%). Eight patients had treatment breaks of 3·5 months to 10 years; in four of six patients, re‐initiation of treatment led to clear benefit. Safety data show slightly greater haematological and constitutional toxicity in PTCL . cDNA microarray studies show unique individual gene expression profiles, minimal overlap between patients, and both induction and repression of gene expression that reversed within 24 h. These data argue against cell death occurring as a result of an epigenetics‐mediated gene induction programme. Together this work supports the safety and activity of romidepsin in T‐cell lymphoma, but suggests a complex mechanism of action.

Romidepsin

Peripheral T-cell lymphoma

Cutaneous T-cell lymphoma

10.1111/bjh.13400

Cite

Citations (58)

Mark Kirschbaum

Papers

Citation

H-Index

i-10 index

Papers

Citation

H-Index

i-10 index